Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced gastrointestinal NETs. The phase 3 CABINET trial demonstrated that Cabometyx ...
Here are 11 statistics on gastroenterology net revenue per case for ASCs, according to VMG Health’s Multi-Specialty ASC Intellimarker 2017.
TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib. A phase II trial of ...
Here are 14 statistics on gastroenterology net revenue per case and case volume across the U.S., according to VMG Health’s “Multi-Specialty ASC Intellimarker 2017.” ...
Novartis today announced that the United States Food and Drug Administration (FDA) approved Afinitor ® (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, ...
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study Between September 2015 and March 2017, a ...
The gastrointestinal neuroendocrine tumors market is experiencing steady growth driven by increasing disease prevalence, improved diagnostic capabilities, and rising awareness of targeted therapies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback